Aclaris Therapeutics ACRS Drug Candidate Ati9494 — Research And Development Project Spend
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept acrs:ResearchAndDevelopmentProjectSpend.
The official record: Aclaris Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aclaris Therapeutics's drug candidate ati9494 — research and development project spend.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aclaris Therapeutics's drug candidate ati9494 — research and development project spend?
- Aclaris Therapeutics (ACRS) reported drug candidate ati9494 — research and development project spend of $2.23M in Q1 2026.
- How has Aclaris Therapeutics's drug candidate ati9494 — research and development project spend changed year-over-year?
- Aclaris Therapeutics's drug candidate ati9494 — research and development project spend increased by 228.2% year-over-year, from $678K to $2.23M.
- What does drug candidate ati9494 — research and development project spend mean?
- This metric represents the total direct costs and allocated resources dedicated to the research and development of a specific drug candidate within the clinical-stage pipeline. It captures the financial investment required to advance a therapeutic asset through various stages of preclinical or clinical testing. Tracking this spend provides insight into the company's capital allocation strategy and the relative priority assigned to specific immuno-inflammatory programs.